|
Скачать 2.66 Mb.
|
http://www.nhlbi.nih. gov/guidelines/asthma/asthsumm.htm 59. Flaherman V., Rutherford G. W. A meta-analysis of the e? ect of high weight on asthma // Arch. Dis. Child. 2006. V. 91. P. 334–339. 60. Fundamental Immunology / Ed. by Paul W. E. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2003 — p. 1701 Global strategy for asthma management and prevention: GINA executive summary // Eur. Respir. J. 2008. V. 31. P. 143–178. 61. The Global Asthma Report 2011. Paris, France: The International Union Against Tuberculosis and Lung Disease, 2011. http://www.theunion.org/ index.php/resources/index.php?id=651&cid=1839&? d=57&task=downloa d&option=com_? exicontent&Itemid=43&lang=en 62. Guilbert T. W., Morgan W. J., Zeiger R. S., et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma // J. Allergy Clin. Immunol. 2004. V. 114. P. 1282-1287. 63. Gustafsson D., Sjoberg O., Foucard T. et al. Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective tollow-up to 7 years of age. // Allergy. 2000. V.55. P. 240–245. 64. Illi S., von Mutius E., Lau S., et. al. The pattern of atopic sensitisation is associated with the development of asthma in childhood // J. Allergy Clin. Immunol. 2001. V. 108. P. 709–714. 65. Illi S, von Mutius E., Lau S. et al.; Multicentre Allergy Study (MAS) group. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study // Lancet. 2006. V. 368. P. 763–770. 66. Illi S., von Mutius E., Lau S. et al.; Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma // J. Allergy Clin. Immunol. 2004. V. 113. P. 925–931. 67. Knorr B., Franchi L. M., Bisgaard H. et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years // Pediatrics. 2001. V. 108. P. E48. 68. Kramer M. S. Maternal antigen avoidance during pregnancy for preventing atopic disease in infants of women at high risk // Cochrane Database Syst. Rev. 2000. № 2. CD000133. 69. Martinez F. D. What have we learned from the Tucson Children»s Respiratory Study? // Paediatr. Respir. Rev. 2002. V. 3. № 3. P. 193–197. 70. Matricardi P. M., Rosmini F., Panetta V. et al. Hay fever and asthma in relation to markers of infection in the United States // J. Allergy Clin. Immunol. 2002. V. 110. P. 381–387. 71. Meiler F., Zimmermann M., Blaser K. et al. T-cell subsets in the pathogenesis of human asthma // Curr. Allergy Asthma Rep. 2006. V. 6. P. 91–96. 72. Morgan W. J., Crain E. F., Gruchalla R. S. et al. Results of a home-based environmental intervention among urban children with asthma // N. Engl. J. Med. 2004. V. 351. P. 1068-1080. 73. Morikawa A., Nishima S.; Japanese Society of Pediatric Allergy and Clinical Immunology. New Japanese pediatric guidelines for the treatment and management of bronchial asthma // Pediatr. Int. 2007. 49. № 6. P. 1023-1031. 74. Moshammer H., Hoek G., Luttmann-Gibson H. et al. Parental smoking and lung function in children: an international study // Amer. J. Respir. Crit. Care Med. 2006. V. 173. P. 1255-1263. 75. Murray C. S., Poletti G., Kebadze T. et al. Study of modi? able risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children // Thorax. 2006. V. 61. P. 376–382. 76. National Asthma Education and Prevention Program. E? ects of early treatment on the progression of asthma // J. Allergy Clin. Immunol. 2002. V. 110. № 5. Suppl. P. 196–219. 77. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma- Summary Report 2007 // J. Allergy Clin. Immunol. 2007. V. 120. № 5. Suppl. P. 194–138. 78. Ober C., Ho? jan S. Asthma genetics 2006: the long and winding road to gene discovery // Genes. Immun. 2006. V. 7. P. 95–100. 79. Martin P., Matheson M., Gurrin L., et al. Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: A prospective cohort study over 4 decades // JACI. 2011. V. 127. P. 1473-1479. 80. Pulmonary Rehabilitation // Eur. Respir. Mon. / Ed. by Donner C. F., Decramer M. 2000. V. 13. P. 1–199. 81. Ressel G. W.; Centers for Disease Control and Prevention; National Asthma Education and Prevention Program. NAEPP updates guidelines for the diagnosis and management of asthma // Amer. Fam. Physician. 2003. V. 68. № 1. P. 169–170. 82. Roche N., Morel H., Martel P., Godard P. Clinical practice guidelines: medical follow-up of patients with asthma — adults and adolescents // Respir. Med. 2005. V. 99. № 7. P. 793–815. 83. Saglani S., Malmstro»m K., Pelkonen A. S. et al. Airway remodeling and in? ammation in symptomatic infants with reversible air? ow obstruction // Amer. J. Respir. Crit. Care Med. 2005. V. 171. P. 722–727. 84. Sato K., Kusaka Y.; Japanese Society of Occupational and Environmental Allergy. A proposal for guideline for prevention of allergic occupational asthma in conformity with the globally harmonized system of classi? cation and labelling of chemicals (GHS) // Int. J. Immunopathol. Pharmacol. 2007. V. 20. № 2. Suppl. 2. P. 51–53. 85. Simons F. E., Villa J. R., Lee B. W. et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study // J. Pediatr. 2001. V. 138. P. 694–698. 86. Sotirios F., Skylogianni E., Panagiotopoulou E., et al. Forced oscillations for assessing bronchodilator responsiveness in children with asthma // Eur. Resp. J. 2010. V. 36, suppl. 54. P. 87. Sorkness C. A., Lemanske R. F. Jr., Mauger D. T. et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial // J. Allergy Clin. Immunol. 2007. V. 119. P. 64–72. 88. Straub D. A., Minocchieri S., Moeller A. et al. The e? ect of mon-telukast on exhaled nitric oxid and lung function in asthmatic children 2 to 5 years old // Chest. 2005. V. 127. P. 509–514. 89. Straub D. A., Moeller A., Minocchieri S. et al. The e? ect of mon- telukast on lung function and exhaled nitric oxide in infants with early childhood asthma // Eur. Respir. J. 2005. V. 25. P. 289–294. 90. Strek M. E.; Antileukotriene Working Group. Consensus guidelines for asthma therapy // Ann. Allergy Asthma Immunol. 2001. V. 86. № 6. Suppl. 1. P. 40–44. 91. Theodoropoulos D. S., Lockey R. F. Allergen immunotherapy: guidelines, update, and recommendations of the World Health Organization // Allergy Asthma Proc. 2000. V. 21. № 3. P. 159–166. 92. Van Adelsberg J., Moy J., Wei L. X. et al. Safety, tolerability, and exploratory e? cacy of montelukast in 6-to 24-month-old patients with asthma // Curr. Med. Res. Opin. 2005. V. 21. P. 971–979. 93. Van Asperen P., Cahill A., Alexander K., Henry R.; Children,s Hospitals Australasia and the Clinical Forum on Asthma. Discharge guidelines for children with acute asthma: a consensus statement // J. Paediatr. Child Health. 2001. V. 37. № 6. P. 539–541. 94. Van Asperen P. P., Mellis C. M., Sly P. D.; Thoracic Society of Australia and New Zealand. The role of corticosteroids in the management of childhood asthma // Med. J. Aust. 2002. V. 176. № 4. P. 168–173. 95. Van der Molen T., Ostrem A., Stallberg B. et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of asthma // Prim. Care Respir. J. 2006. V. 15. № 1. P. 35–47. 96. Verberne A. A., Frost C., Duiverman E. J. et al. Addition of sal-meterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group // Amer. J. Respir. Crit. Care Med. 1998. V. 158. P. 213–219. 97. von Berg A., Koletzko S., Filipiak-Pittro? B. et al. Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three- year results of the German Infant Nutritional Intervention Study // J. Allergy Clin. Immunol. 2007. V. 119. P. 718–725. 98. Woodcock A., Lowe L. A., Murray C. S. et al. Early life environmental control: e? ect on symptoms, sensitization, and lung function at age 3 years // Amer. J. Respir. Crit. Care Med. 2004. V. 170. P. 433–439. 99. Woods R. K., Thien F. C., Abramson M. J. Dietary marine fatty acid (? sh oil) for asthma // Cochrane Database Syst. Rev. 2000. № 4. CD001283. 100. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergic in Childhood (ISAAC). Steering Committee // Lancet. 1998. V. 351. P. 1225-1232. |